Baader Bank Aktiengesellschaft Cardiff Oncology, Inc. Transaction History
Baader Bank Aktiengesellschaft
- $1.31 Billion
- Q2 2025
A detailed history of Baader Bank Aktiengesellschaft transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Baader Bank Aktiengesellschaft holds 10,022 shares of CRDF stock, worth $38,885. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,022Holding current value
$38,885% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CRDF
# of Institutions
123Shares Held
29.5MCall Options Held
900KPut Options Held
234K-
Commodore Capital LP New York, NY5.38MShares$20.9 Million1.66% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.12MShares$12.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$10.2 Million0.0% of portfolio
-
Blair William & CO Chicago, IL2.52MShares$9.79 Million0.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.45MShares$5.61 Million0.01% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $168M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...